ENG/中
老虎证券
行情
交易
收费
优惠与活动
帮助
TigerAI
专栏
关于
登录
立即注册
Toggle
美股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
Alpha Tau Medical Warrant
1.21
-0.1600
-11.68%
成交量:
3.98万
成交额:
4.93万
市值:
8,516.05万
市盈率:
-2.32
高:
1.38
开:
1.35
低:
1.15
收:
1.37
52周最高:
1.50
52周最低:
0.1300
股本:
7,038.06万
流通股本:
7,038.06万
量比:
1.12
换手率:
0.06%
股息:
- -
股息率:
- -
每股收益(TTM):
-0.5213
净资产收益率:
--
总资产收益率:
--
市净率:
--
市盈率(LYR):
- -
数据加载中...
总览
公司
新闻资讯
公告
Alpha Tau Medical将在ASCO GI 2026研讨会上公布两项新积极成果 展示蒙特利尔胰腺癌Alpha Dart®研究的免疫保护与高疾病控制率
美股速递
·
01/06
Alpha Tau向FDA提交Alpha Dart®治疗复发性皮肤鳞状细胞癌的首个上市前审批模块
美股速递
·
01/05
Alpha Tau获得FDA批准启动局部复发前列腺癌患者试验
美股速递
·
2025/12/02
Alpha Tau Medical成功治疗美国多中心胰腺癌临床试验首例患者
美股速递
·
2025/09/02
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易,超低佣金,新手也能轻松开启投资。在老虎证券, 1 美元起投资美股,24/5 无时差交易美股,澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易,超低佣金,新手也能轻松开启投资。在老虎证券, 1 美元起投资美股,24/5 无时差交易美股,澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/DRTSW/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"DRTSW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DRTSW\",,,,,undefined,":{"symbol":"DRTSW","market":"US","secType":"STK","nameCN":"Alpha Tau Medical Warrant","latestPrice":1.21,"timestamp":1772226000000,"preClose":1.37,"halted":0,"volume":39846,"delay":0,"changeRate":-0.1167883211678833,"floatShares":70380571,"shares":70380571,"eps":-0.5213,"marketStatus":"休市中","change":-0.16,"latestTime":"02-27 16:00:00 EST","open":1.35,"high":1.38,"low":1.15,"amount":49270.6757,"amplitude":0.167883,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.5213,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1772442000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.37,"volumeRatio":1.1178064724603514},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DRTSW\",,,,,undefined,":{"symbol":"DRTSW","floatShares":70380571,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.1178064724603514,"shares":70380571,"dividePrice":0,"high":1.38,"amplitude":0.167883,"preClose":1.37,"low":1.15,"week52Low":0.13,"pbRate":"--","week52High":1.5,"institutionHeld":0,"latestPrice":1.21,"eps":-0.5213,"divideRate":0,"volume":39846,"delay":0,"ttmEps":-0.5213,"open":1.35,"prevYearClose":0.34,"prevWeekClose":1.12,"prevMonthClose":1.21,"prevQuarterClose":0.34,"fiveDayClose":1.12,"twentyDayClose":0.954,"sixtyDayClose":0.34},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DRTSW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DRTSW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DRTSW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DRTSW\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1152568891","title":"Alpha Tau Medical将在ASCO GI 2026研讨会上公布两项新积极成果 展示蒙特利尔胰腺癌Alpha Dart®研究的免疫保护与高疾病控制率","url":"https://stock-news.laohu8.com/highlight/detail?id=1152568891","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152568891?lang=zh_cn&edition=fundamental","pubTime":"2026-01-06 22:08","pubTimestamp":1767708521,"startTime":"0","endTime":"0","summary":"Alpha Tau Medical宣布,其即将在ASCO GI 2026研讨会上展示的两项研究取得了新的积极结果。这些成果重点揭示了Alpha Dart®蒙特利尔胰腺癌研究中体现的免疫保护特性与卓越疾病控制效果。\n研究数据显示,该疗法在维持患者免疫系统功能的同时,实现了较高的疾病控制水平。这一突破为胰腺癌治疗领域提供了新的方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRTS","BK4082","DRTSW"],"gpt_icon":0},{"id":"1128236953","title":"Alpha Tau向FDA提交Alpha Dart®治疗复发性皮肤鳞状细胞癌的首个上市前审批模块","url":"https://stock-news.laohu8.com/highlight/detail?id=1128236953","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128236953?lang=zh_cn&edition=fundamental","pubTime":"2026-01-05 22:06","pubTimestamp":1767622002,"startTime":"0","endTime":"0","summary":"Alpha Tau Medical已向美国食品药品监督管理局(FDA)提交了Alpha Dart®治疗复发性皮肤鳞状细胞癌(cSCC)的首个上市前审批模块。这一重要进展标志着该创新疗法在监管审批流程中迈出了关键一步。\nAlpha Dart®作为一种新型放射治疗技术,专注于为复发型皮肤鳞状细胞癌患者提供精准靶向治疗。此次提交的模块涵盖了产品的核心数据,为后续审批奠定了坚实基础。\n该公司的突破性技术平台通过α粒子放射疗法直接作用于肿瘤细胞,在早期临床研究中展现出显著疗效。此次监管里程碑将加速该疗法为患者提供创新治疗选择的进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRTS","DRTSW","BK4082"],"gpt_icon":0},{"id":"1160292703","title":"Alpha Tau获得FDA批准启动局部复发前列腺癌患者试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1160292703","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160292703?lang=zh_cn&edition=fundamental","pubTime":"2025-12-02 22:02","pubTimestamp":1764684124,"startTime":"0","endTime":"0","summary":"Alpha Tau获得FDA批准,启动针对局部复发前列腺癌患者的临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","DRTSW","DRTS"],"gpt_icon":0},{"id":"1151041494","title":"Alpha Tau Medical成功治疗美国多中心胰腺癌临床试验首例患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1151041494","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151041494?lang=zh_cn&edition=fundamental","pubTime":"2025-09-02 20:31","pubTimestamp":1756816268,"startTime":"0","endTime":"0","summary":"Alpha Tau Medical成功治疗美国多中心胰腺癌临床试验首例患者","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","DRTS","DRTSW"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}]}}